Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more .

Wintermute Forges Promising Collaboration to Combat Catheter-Associated Infections

Wintermute teams up with top surface scientist to create antimicrobial medical device coatings and combat widespread hospital infections.

Wintermute Biomedical
March 10, 2024

In an exciting development, Wintermute has engaged with renowned surface scientist Professor Peter Kingshott at Swinburne University of Technology. The collaboration aims to test the antimicrobial efficacy of Wintermute's proprietary fatty acid compounds when chemically attached to surfaces, with a particular focus on medical devices.

Professor Kingshott is a pioneering expert in modulating surfaces of medical implants and surfaces for infection control. This partnership holds the potential to be a game-changer in the fight against catheter-associated urinary tract infections (CAUTIs), a significant healthcare challenge. Urinary tract infections are the most common type of healthcare-associated infection, and among UTIs acquired in hospitals, approximately 75% are associated with a urinary catheter (CDC).

The project will explore the attachment of Wintermute's fatty acid compounds to surfaces, such as urinary catheters, and evaluate their ability to prevent microbial growth and biofilm formation. By harnessing the antimicrobial properties of these compounds, the collaboration aims to develop a novel approach to mitigate the risk of CAUTIs, which can lead to severe complications and prolonged hospital stays.

Preliminary studies conducted by Wintermute demonstrate that the antimicrobial activity of the compounds is retained when coated on surfaces. These findings suggest a promising application for Wintermute's antimicrobial solutions in controlling CAUTIs, though further development and rigorous testing are essential to fully realize the impact of this innovative approach.

"We are thrilled to partner with Professor Kingshott and leverage his expertise in surface modification," said Dr. Alyce Mayfosh, Chief Scientific Officer at Wintermute. "This collaboration aligns with our mission to develop cutting-edge solutions that improve patient outcomes and enhance healthcare practices."

As Wintermute continues to push the boundaries of innovation, this collaboration with Swinburne University represents a significant step forward in the company's efforts to combat catheter-associated infections and improve the quality of life for patients worldwide.

If you would like to find out more about our programs, please contact us here.